Search Results
Your search for ,OUr matches 10643 pages
Showing 1801 - 1850Lung Cancer Screening May Be More Cost-Effective When Using Risk Model–Based Strategies
Risk model–based lung cancer screening strategies may be more cost-effective than current recommendations that are based solely on the patient’s age and smoking history, according to a new study published by Toumazis et al in the Annals of Internal Medicine. The findings also suggested that...
COVID-19 Outcomes Across Pandemic Phases in European Patients With Breast Cancer
In a study using data from the European OnCovid registry reported in the Journal of Clinical Oncology, Tagliamento et al found that the severity of COVID-19 infection in patients with breast cancer decreased during the Omicron variant phase of the pandemic. In addition, a full vaccine course...
Oncologists Look for Strong Health-Care Priorities in the State of the Union Address
In anticipation of President Joseph R. Biden’s State of the Union Address tonight, ASCO is urging the president to keep cancer care and research as top national priorities. Oncologists have seen how clinical research has improved prevention, detection, and treatment for millions of Americans and...
Expert Point of View: Imane H. El Dika, MD
The sessions’ invited discussant, Imane H. El Dika, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, said the results of the two trials in advanced biliary tract cancer were clear, and did not change the current standard of care of durvalumab combined with...
SBRT for Patients With Primary Lung Neuroendocrine Tumors
Researchers have found that stereotactic body radiotherapy (SBRT) may be an effective treatment for patients with early-stage lung neuroendocrine tumors, according to a new study published by Oliver et al in the International Journal of Radiation Oncology • Biology • Physics. Background Primary...
Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry
Biorepositories created to support precision cancer research through their vast stores of genomic data may lack sufficient representation of cancer distribution among racial and ethnic minorities, according to a new study published by Cheung et al in npj Precision Oncology. The investigators also...
ctDNA as a Prognostic Marker in Intermediate-Risk Rhabdomyosarcoma
In a study from the Children’s Oncology Group reported in the Journal of Clinical Oncology, Abbou et al found that measuring circulating tumor DNA (ctDNA) in intermediate-risk rhabdomyosarcoma was feasible and that the presence of ctDNA prior to treatment was associated with poorer prognosis. As...
Massage Therapy May Improve Symptom Burden for Pediatric Patients With Hematologic and/or Oncologic Conditions
A new study from University Hospitals (UH) Connor Whole Health found children, adolescents, and young adults with cancer or sickle cell disease treated at a pediatric academic medical center reported clinically significant reductions in pain, stress, and anxiety in response to massage therapy....
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
Consuming Ultraprocessed Foods May Be Linked to Increased Cancer Risk and Mortality
Higher consumption of ultraprocessed foods may be linked to increased cancer burden and mortality, according to a new, UK-based study published by Chang et al in eClinicalMedicine. Ultraprocessed foods are food items which have been heavily processed during their production—such as fizzy drinks,...
Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC
The EGFR tyrosine kinase inhibitor osimertinib may improve rates of disease-free survival and reduce the risk of recurrence in patients with resected, EGFR-mutant non–small cell lung cancer (NSCLC), according to a new exploratory analysis of the ADAURA trial published by Roy S. Herbst, MD, PhD,...
Canadian Trial Highlights Adverse Outcomes in Survivors of Childhood Medulloblastoma
In a population-based study reported in the Journal of Clinical Oncology, Coltin et al found that survivors of childhood medulloblastoma in Ontario were at an increased risk of numerous adverse health outcomes compared with matched noncancer controls. Study Details In the study, all 5-year...
Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts
Compared to other common supplemental screening methods, breast magnetic resonance imaging (MRI) was superior at detecting breast cancer in patients with dense breasts, according to a new study published by Hussein et al in Radiology. Background Breast cancer is one of the leading causes of cancer...
Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years
Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology • Biology • and Physics. Background Radiation therapy often is given...
Momelotinib May Effectively Reduce Anemia and Other Symptoms for Patients With Myelofibrosis
The targeted therapy momelotinib may offer clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, for patients with myelofibrosis, according to a novel study published by Srdan Verstovsek, MD, PhD, and colleagues in The Lancet. The findings support...
Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer
In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...
Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid Cancer
In a phase II trial (NRG/RTOG 0912) reported in The Lancet Oncology, Sherman et al found that the addition of pazopanib to concurrent radiotherapy and paclitaxel did not improve overall survival in patients with anaplastic thyroid cancer. Study Details In the U.S. multicenter, double-blind trial,...
New Study Shows Increased Cancer Mortality Among Patients With Type 2 Diabetes in England
New research shows that patients with type 2 diabetes may experience a substantially higher rate of cancer mortality than the general population—by 18% for all cancers combined, 9% for breast cancer, and as much as 2.4-fold for colorectal cancer—according to a new study published by Ling et al in...
Trends in Use of Next-Generation Sequencing in U.S. Patients According to Genetic Ancestry
In a study reported in a letter to the editor in The New England Journal of Medicine, Mata et al found that U.S. individuals of African ancestry and Hispanic patients made up an increasing proportion of patients undergoing next-generation sequencing of tumor samples over a 9-year period ending in...
Analysis of Mutations Associated With High Tumor Mutation Burden in Microsatellite-Stable Gastrointestinal Cancers
In a study reported in The Lancet Oncology, Wang et al identified mutations linked to high tumor mutation burden in microsatellite-stable (MSS) gastrointestinal cancers that may be associated with efficacy of immune checkpoint inhibitor therapy. Study Details Molecular alterations in 48,606...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
A Serendipitous Opportunity Steers a Theater Major Into Oncology
Lymphoma expert Jeremy S. Abramson, MD, was born in Westchester County, New York, but soon after, his family relocated to Bergen County, New Jersey, where he spent his formative years. “I attended Tenafly High School and had dual passions: one was the natural sciences and the other on the...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Significant Benefit With Addition of Daratumumab to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in the Journal of Clinical Oncology by Pieter Sonneveld, MD, PhD, of Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and colleagues, the final overall survival analysis of the phase III CASTOR trial has shown a significant benefit of the addition of daratumumab to...
Risks of Cardiovascular and Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy
In a single academic hospital network retrospective case-control study reported in JACC:CardioOncology, Charlotte Lee, MD, of Columbia University Irving Medical Center, New York, along with senior author Tomas Neilan, MD, MPH, of Massachusetts General Hospital and colleagues found that patients...
Northwell Cancer Institute Welcomes New Chief of Hematologic Malignancies
Northwell Health recently appointed Douglas Gladstone, MD, a leader in hematology and medical oncology, as Chief of Hematologic Malignancies at the Northwell Health Cancer Institute. Prior to joining Northwell, Dr. Gladstone served for 14 years as Clinical Director of the outpatient bone marrow...
Expert Point of View: Solange Peters, MD, PhD
The formal discussant of ARC-7 was Solange Peters, MD, PhD, Chair of Medical Oncology, Centre D’Oncologie Chuv, Lausanne University Hospital, Switzerland, and President of the European Society for Medical Oncology. Dr. Peters described how TIGIT (T-cell immunoglobulin and ITIM domain) plays a role ...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
2022 ASH Annual Meeting and Exposition: Focus on Lymphoma
On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in lymphoma.
Is the Risk of Suicide Higher Among Individuals With Cancer?
According to a large new study led by researchers at the American Cancer Society, the risk of suicide for individuals diagnosed with cancer in the United States is 26% higher compared with the general population. Geographic, racial/ethnic, socioeconomic, and clinical characteristics contributed to...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, said that the study points the way to further exploration of the benefit of adding immunotherapy to treatment after patients develop resistance to CDK4/6 inhibitors for ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Addressing the Continued Existence of Racial Inequities in Cancer Care
The opportunity to write this commentary on cancer disparities comes at a sorrowful time for me. Despite practicing as a surgical oncologist for more than 20 years and understanding the unequal burden that cancer visits on the Black community, I was woefully unprepared for the premature death of my ...
Ensuring a More Diverse, Equitable, and Inclusive Workforce Within the SWOG Cancer Research Network
For more than 2 decades, Don S. Dizon, MD, FACP, FASCO, has devoted his medical career to the care of women’s cancers and the sexual health of cancer survivors of all genders and sexual identities. Early in his career, Dr. Dizon founded the Center for Sexuality, Intimacy, and Fertility at Women...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Ovarian Cancer May Be Linked to Pathogenic Microbe Colonization in Reproductive Tract
A specific colonization of pathogenic microbes in the reproductive tract may be commonly found in patients with ovarian cancer, according to a new study published by Asangba et al in Scientific Reports. The discovery strengthens evidence that the bacterial component of the microbiome may be an...
Study Suggests Ibrutinib May Obviate Need for ASCT in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Frequency and Dosage of Radiotherapy in Chemoradiotherapy for Limited-Stage SCLC
As reported in the Journal of Clinical Oncology by Jeffrey Bogart, MD, and colleagues, the phase III CALGB 30610/RTOG 0538 trial has shown no significant difference in overall survival with 70-Gy once-daily vs 45-Gy twice-daily radiotherapy in a chemoradiotherapy regimen for limited-stage small...
Molecular Tumor Board Offers Assistance That May Boost Effectiveness of Precision Oncology
The field of precision oncology has become so complex that even experienced oncologists can find it challenging to decipher the molecular test results of tumor tissue and navigate treatment options for patients. Investigators revealed that a new program may aid gastrointestinal cancer physicians in ...
2022 ASH Annual Meeting and Exposition: Focus on Multiple Myeloma
On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in multiple myeloma.
Novel AI Tool May Predict Risk of Lung Cancer Using Low-Dose CT Scan Data
Researchers have developed and tested an artificial intelligence (AI) tool known as Sybil, which may accurately predict the risk of lung cancer for individuals with or without a significant smoking history using data from low-dose chest computed tomography (CT) scans, according to a new study...
Circulating Tumor DNA Profiling and Outcomes in CNS Lymphoma
In a German study reported in the Journal of Clinical Oncology, Mutter et al found that circulating tumor DNA (ctDNA) identified prior to and during treatment was associated with poorer outcomes in patients with central nervous system (CNS) lymphoma. Study Details The study included 92 patients...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
